see bellow
U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCorporate Conference Call Scheduled Today at 10:00 AM PT, November 13, 2013